Evofem Biosciences, Inc. (EVFM) Analyst Estimates Annual - Discounting Cash Flows
EVFM
Evofem Biosciences, Inc.
EVFM (OTC)
Period Ending: 2026
12-31
2025
12-31
2024
12-31
2023
12-31
2022
12-30
2021
12-30
2020
12-30
Number of Analysts 1 1 1 1 1 1 1
Estimated Revenue
Low 241.1 193.3 124.8 18.57 33.2 8.08 1.9
Average 241.1 193.3 124.8 18.57 33.2 8.08 1.9
High 241.1 193.3 124.8 18.57 33.2 8.08 1.9
Estimated EBITDA
Low -151.3 -121.3 -78.32 -15.74 -28.15 -6.85 -1.61
Average -151.3 -121.3 -78.32 -15.74 -28.15 -6.85 -1.61
High -151.3 -121.3 -78.32 -15.74 -28.15 -6.85 -1.61
Estimated EBIT
Low -159.4 -127.8 -82.51 -16.25 -29.06 -7.07 -1.66
Average -159.4 -127.8 -82.51 -16.25 -29.06 -7.07 -1.66
High -159.4 -127.8 -82.51 -16.25 -29.06 -7.07 -1.66
Estimated Net Income
Low 369,250 184,625 -128,435 -752.4 -95,977 -263,153 -349,966
Average 369,250 184,625 -128,435 -752.4 -95,977 -263,153 -349,966
High 369,250 184,625 -128,435 -752.4 -95,977 -263,153 -349,966
Estimated SGA Expenses
Low 1,174 941.4 607.9 798.1 1,427 347.3 81.51
Average 1,174 941.4 607.9 798.1 1,427 347.3 81.51
High 1,174 941.4 607.9 798.1 1,427 347.3 81.51
Estimated EPS
Low 57.5 28.75 -20 -7.8 -995 -2,728 -3,628
Average 57.5 28.75 -20 -7.8 -995 -2,728 -3,628
High 57.5 28.75 -20 -7.8 -995 -2,728 -3,628
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program